纳米粒子以喘为目标
Samantha K Hamrick1, Michael A Thompson1, Vincent M Rotello2
1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, United States.
概括
纳米颗粒为向性喘治疗提供了一个有前途的新方法,克服了气道的传递挑战. 对纳米粒子安全性和设计的进一步研究对于这种慢性肺病的有效治疗至关重要.
科学领域:
- 肺部医学 肺部医学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 全球有3.4亿人患有喘,其特点是气道过度反应,重塑和粘液.
- 目前的喘治疗有副作用,对一些患者是无效的,需要新的治疗方法.
- 需要针对性地将药物输送到特定的气道细胞,以克服粘液和加厚.
研究的目的:
- 审查纳米粒子 (NP) 在喘治疗中的当前应用.
- 找出改善NP设计和用于喘的利用机会.
- 评估NP作为喘传递系统和治疗方法的潜力.
主要方法:
- 关于在喘中使用纳米粒子的当前文献的综述.
- 对药物输送的NP特征 (材料,大小,电荷,表面变化) 的分析.
- 评估NP的安全性,包括炎症,毒性和器官积累.
主要成果:
- 纳米粒子具有高度可定制性,可用于传递各种治疗载荷 (核酸,蛋白质,小分子).
- NPs显示出作为喘治疗药物本身的潜力.
- 目前正在进行的临床试验和FDA批准的NP疗法表明了潜在的安全性和有效性.
结论:
- 纳米粒子代表了针对性喘治疗的有希望的解决方案,解决了传递挑战.
- 仔细考虑NP安全概况对于临床转化至关重要.
- 为了有效的喘管理,需要进一步优化NP设计和应用.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
240
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
240
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Inhaled Medications
237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
Asthma: Pathogenesis and Management
361
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
361
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Antiasthma Drugs: Muscarinic Receptor Antagonists
249
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
249


